No abstract

No abstract

Aim: To study the efficacy of Infliximab on the severity and occurrence of Acute Anterior Uveitis in HLA B27 positive patients. Materials and Methods: This is a prospective observational study done on 30 patients with acute anterior uveitis who were HLA B27 positive presenting to Uvea and Retina Services at Regional Institute of Ophthalmology Government Ophthalmic Hospital, Chennai between April 2013 to May 2015. Of which 16 patients were on Infliximab therapy (3-5mg/kg) for Ankylosing Spondylitis, 6 patients were on Tablet Sulfasalazine for the articular symptoms of Ankylosing Spondylitis and 8 patients were not on any medication and were retrospectively diagnosed as HLA-B27 positive. A detailed history, systemic examination, ocular examination using Slit lamp, 90D biomicroscopy, blood investigations for HLA B27 and MRI Sacroiliac joint was done. Patients were started on topical corticosteroids and cycloplegics, the response noted and followed up for 3 months. Results: Severity of uveitis did not show any variation between groups that were on infliximab and sulfasalazine and those who were not on any treatment. Patients in the three groups responded dramatically well to topical corticosteroids and cycloplegics. Conclusion: Infliximab (3-5mg/kg) regime used for the control of symptoms of Ankylosing Spondylitis neither prevents the occurrence nor decreases the severity of Acute Anterior Uveitis in HLA-B27 patients. Further studies are needed to establish the safe and effective dosage of Infliximab to prevent the occurrences of Acute Anterior Uveitis in HLA B27 patients.

No abstract

Aim: To establish the role of Anti Tuberculous therapy (ATT) in Eales disease. Methods: This is a prospective study in which 15 patients with Eales disease of the age group 18-40 years were included. This study was conducted from January 2014 to June 2016. In our study, all patients were previously treated with a full course of steroids and four patients were treated with Pan retinal photocoagulation for neovascularisation in addition to the steroid therapy but had recurrences of inflammation. All the above patients were treated with Category 1 Anti Tuberculous therapy and oral prednisolone in tapering doses. The patients were reviewed at 1 and 6 months while on ATT and for every 2 months for one year after completion of ATT. The presence or absence of active inflammation was assessed and the outcome was analyzed. Results: In our study, 11 patients had complete resolution of inflammation with ATT and showed no recurrence of inflammation during the follow up period of one year. Two patients developed neovascularisation and Pan retinal photocoagulation was given and was considered as non response to treatment. One patient developed vitreous hemorrhage. One patient had persistent inflammation and showed no resolution of inflammation while on ATT. Conclusion: With the above study we conclude that anti tuberculous therapy should be considered in patients with Eales disease with recurrent inflammation for preventing further recurrences and reducing ocular morbidity due to complications.